TY - JOUR
T1 - Endovascular Therapy for Infrainguinal Artery Disease with Coronary Devices
AU - Giordano, Arturo
AU - Ferraro, Paolo
AU - Corcione, Nicola
AU - Messina, Stefano
AU - Maresca, Gennaro
AU - Coscioni, Enrico
AU - Avellino, Raffaella
AU - Giordano, Gabriele
AU - Peruzzi, Mariangela
AU - Biondi-Zoccai, Giuseppe
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Several devices are available for infrainguinal endovascular therapy, with drug-eluting stents (DES) among the most promising. Bioresorbable vascular scaffolds (BVS) may further improve outcomes. We have liberally used in our practice coronary DES and BVS for infrainguinal endovascular therapy and hereby report our preliminary results. We conducted an observational study by retrospectively identifying characteristics of patients undergoing infrainguinal implantation of coronary DES or BVS. We compared the risk of major adverse events (MAE: death, amputation, or target vessel revascularization [TVR]) and components of MAE in the overall sample and after propensity matching. We included a total of 204 patients (207 limbs), 148 (72.5%) treated with DES and 56 (27.5%) with BVS. Bivariate analysis showed that TVR was less common in the DES group (41.9% vs 18.4%, P =.014). However, propensity-matched analysis showed nearly identical risks of MAE, amputation, TVR, or symptom burden with DES and BVS (all P >.05). In conclusion, the present pilot experience with coronary BVS suggests that they could provide acceptable results for infrainguinal endovascular procedures, comparable to those obtained by their metallic counterpart.
AB - Several devices are available for infrainguinal endovascular therapy, with drug-eluting stents (DES) among the most promising. Bioresorbable vascular scaffolds (BVS) may further improve outcomes. We have liberally used in our practice coronary DES and BVS for infrainguinal endovascular therapy and hereby report our preliminary results. We conducted an observational study by retrospectively identifying characteristics of patients undergoing infrainguinal implantation of coronary DES or BVS. We compared the risk of major adverse events (MAE: death, amputation, or target vessel revascularization [TVR]) and components of MAE in the overall sample and after propensity matching. We included a total of 204 patients (207 limbs), 148 (72.5%) treated with DES and 56 (27.5%) with BVS. Bivariate analysis showed that TVR was less common in the DES group (41.9% vs 18.4%, P =.014). However, propensity-matched analysis showed nearly identical risks of MAE, amputation, TVR, or symptom burden with DES and BVS (all P >.05). In conclusion, the present pilot experience with coronary BVS suggests that they could provide acceptable results for infrainguinal endovascular procedures, comparable to those obtained by their metallic counterpart.
KW - bioresorbable vascular scaffold
KW - drug-eluting stent
KW - endovascular therapy
KW - peripheral artery disease
KW - superficial femoral artery
UR - http://www.scopus.com/inward/record.url?scp=85006078340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006078340&partnerID=8YFLogxK
U2 - 10.1177/0003319716637802
DO - 10.1177/0003319716637802
M3 - Article
AN - SCOPUS:85006078340
VL - 68
SP - 59
EP - 66
JO - Angiology
JF - Angiology
SN - 0003-3197
IS - 1
ER -